Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Trial Profile

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions
  • Acronyms LEN01T
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 23 Dec 2016 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.
    • 20 May 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top